Clinical trials: Immunocompromised Patients
Acquired Immune Deficiency Syndrome Virus
Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir
There are few randomized clinical trials in advanced HIV patients. This is a multicenter, randomized, open clinical trial, comparing 2 parallel groups, to compare the immunological reconstitution and the virological efficacy and…
- Trial name
- NCT02337322
- Testing
- Dolutegravir, Darunavir/r
- Where
- Spain
- Volunteers
- 104 people
- Sponsor
- Juan A. Arnaiz
Pneumonia, Hematologic Malignancy
Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation
The goal of this clinical trial is to learn whether the antibiotic ceftolozane-tazobactam works to treat serious Pseudomonas aeruginosa infections in people with blood cancers or who received a stem cell transplant.
- Conditions
- Pneumonia, Hematologic Malignancy, Pseudomonas Aeruginosa Infection, Bacteremia
- Trial name
- NCT04673175
- Testing
- Ceftolozane / Tazobactam Injection
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Weill Medical College of Cornell University
COVID-19
A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Nirmatrelvir/Ritonavir) for the possible treatment of COVID-19.
- Trial name
- NCT05438602
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 84 sites in United States, Australia and 7 more
- Volunteers
- 158 people
- Sponsor
- Pfizer
Immunocompromised
H1N1sw Vaccine in Adult Transplant Recipients
The trial investigates the efficacy of the adjuvanted H1N1 influenza vaccine Focetria(R) in immunocompromised adults who have undergone solid organ or bone marrow transplantation.
- Trial name
- NCT01069601
- Testing
- Focetria (2x H1N1 vaccine with MF59 adjuvants)
- Where
- Germany
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- HepNet Study House, German Liverfoundation
Immunocompromised, Immunosuppressed
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
- Conditions
- Immunocompromised, Immunosuppressed, Covid-19, SARS-COV-2
- Trial name
- NCT05020145
- Testing
- BNT162b2 (Tozinameran)
- Where
- United States
- Volunteers
- 1,277,747 people
- Sponsor
- Pfizer
Human Papilloma Virus Infection
Immunogenicity of 9-valent HPV Vaccine
Human papillomavirus (HPV) causes the most prevalent sexually transmitted infections in the world. The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes, responsible for causing approximately…
- Trial name
- NCT05439083
- Testing
- 9-valent HPV vaccine
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Talia Sainz Costa
Chronic Disease, Immunocompromised
Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients
AMBU-VAX is a prospective, single-center observational study designed to develop and implement an organizational model for delivering recommended vaccinations within a hospital setting.
- Conditions
- Chronic Disease, Immunocompromised, HIV Infection, Chronic Kidney Disease
- Trial name
- AMBU-VAX (NCT07391046)
- Testing
- Hospital-Based Vaccination Pathway
- Volunteers
- 1,500 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Herpes Labialis
Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients
The purpose of this study is to evaluate the episode duration of a herpes labialis recurrence in immunocompromised patients treated with ME-609 or Acyclovir.
- Trial name
- NCT00735761
- Testing
- ME-609, Acyclovir in ME-609 vehicle (5% acyclovir)
- Volunteers
- 201 people
- Sponsor
- Medivir
Infections, Meningococcal
Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects
The purpose of this study is to investigate the immunogenicity, reactogenicity and safety of the new meningococcal vaccine 134612 in subjects with increased risk of meningococcal disease and compare it to its activity in healthy…
- Trial name
- NCT01641042
- Testing
- Meningococcal vaccine GSK134612
- Where
- 16 sites in United States, Czechia
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Viral Infection, Viral Reactivation
Third Party Viral Specific T-cells (VSTs)
The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.
- Conditions
- Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host
- Trial name
- NCT02532452
- Testing
- Viral Specific VST Infusion
- Where
- 4 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Epstein Barr Virus Associated Non Hodgkin's Lymphoma, Epstein Barr Virus Associated Hodgkin's Lymphoma
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
By combining a variety of agents that potentiate Zidovudine (ZDV), the investigators hope to induce remission in this generally fatal disease.
- Conditions
- Epstein Barr Virus Associated Non Hodgkin's Lymphoma, Epstein Barr Virus Associated Hodgkin's Lymphoma, Post-Transplant Lymphoproliferative Disease
- Trial name
- NCT01964755
- Testing
- Doxorubicin, Methotrexate, Leucovorin
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Miami
RESPIRATORY SYNCYTIAL VIRUS (RSV)
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease
The purpose of this study is to learn about the safety and immunogenicity of a study vaccine (called RSVpreF) in several adult groups.
- Trial name
- MONET (NCT05842967)
- Testing
- RSVpreF
- Where
- 36 sites in United States
- Volunteers
- 885 people
- Sponsor
- Pfizer
Breast Cancer, Colon Cancer
Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy
Background: Drugs given to treat cancer (chemotherapy) can weaken the human immune system. But it can also become weaker because of aging.
- Conditions
- Breast Cancer, Colon Cancer, Bladder Cancer
- Trial name
- NCT01339000
- Testing
- Glycosylated Recombinant Human Interleukin-7, Diphtheria/Tetanus Vaccine, Polio Vaccine
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Candidiasis
Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units
This study will examine whether the anti-fungal drug caspofungin can prevent Candida infections in adult patients in intensive care units (ICUs).
- Trial name
- NCT00099775
- Testing
- Caspofungin
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- National Cancer Institute (NCI)
Tuberculosis
Immunocompetent Versus Immunocompromised Tuberculosis (TB) Patients
Tuberculosis (TB) is caused by Mycobacterium tuberculosis and is one of the top 10 causes of mortality worldwide. It is estimated that in 2017, 10 million people were infected with TB, and 1.6 million died from the disease…
- Trial name
- NCT06709157
- Testing
- P24 antigens and antibody, zeihl - Nelsen stain, culture on Lowenstein jensen media
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Sohag University
Fungus Disease
Surveillance of Fungal Infections in Bone Marrow/Stem Cell and Organ Transplant Recipients
This study will collect data on the incidence (rate of occurrence) of fungal infections in recipients of bone marrow, stem cell or organ transplants.
- Trial name
- NCT00026767
- Where
- United States
- Volunteers
- 217 people
- Sponsor
- National Cancer Institute (NCI)
Arthritis, Rheumatoid, Spondylarthritis
Immunogenicity and Safety of Vaccinations in Immunocompromised Persons
Backgound and relevance of the project: Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are at increased risk of contracting infections.
- Conditions
- Arthritis, Rheumatoid, Spondylarthritis, Vasculitis
- Trial name
- NCT01947465
- Testing
- Hepatitis A vaccine and tetanus vaccine
- Where
- 10 sites in Switzerland
- Volunteers
- 645 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Acute Respiratory Failure, Immunocompromised Patients
Empirical Steroids and/or Antifungals in Immunocompromised Patients With Acute Respiratory Failure From Undetermined Etiology: a Multicenter Double-blind Randomized Controlled Trial
Acute respiratory failure (ARF) is the leading reason of ICU admission in immunocompromised patients. Failure to identify the ARF etiology is associated with increased mechanical ventilation and mortality rates.
- Trial name
- EFRAIM II (NCT04680884)
- Testing
- Experimental for steroid, Experimental for antifungals, Experimental for steroids and antifungals
- Volunteers
- 420 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immunocompromised Patients
A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies in Prophylaxis and Curative of Covid-19 (COVIMAB)
Absence of anti-SARS-CoV-2 vaccine response or insufficient vaccine response may occur in immunocompromised patients. Being at high risk of a severe form of Covid-19, they may be eligible to receive recombinant anti-SARS-CoV-2…
- Trial name
- COVIMAB (NCT05439044)
- Testing
- Data collection
- Where
- France
- Volunteers
- 4,235 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mycoses
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)
This phase II study will be conducted to: 1. evaluate the pharmacokinetics, safety, tolerance, and efficacy of different dosing schedules of Posaconazole in immunocompromised hosts with a variety of refractory invasive fungal…
- Trial name
- NCT00034671
- Testing
- Posaconazole oral suspension
- Volunteers
- 98 people
- Sponsor
- Merck Sharp & Dohme LLC